Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Curr Pharm Des. 2016;22(14):2152–2159. doi: 10.2174/1381612822666160127114237

Figure 2.

Figure 2

Cholinergic modification of lung cancer cell growth. H82 small cell lung carcinoma cells were plated in 96-well culture plates and cell proliferation measured after specified drug treatments. Cell numbers were measured at 0, 6, 12 days using the MTS assay. A. The nicotinic agonist nicotine; B. The muscarinic agonist carbachol; C. The nicotinic antagonist mecamylamine; D. The muscarinic antagonist atropine; E. The choline transport inhibitor hemicholinium-3; F. The vesicular acetylcholine transporter inhibitor (VAChT) vesamicol. * p<0.05 by Neuman-Keuls test following ANOVA. All data are expressed as the mean ± SE of twelve replicates. Drug concentrations as shown in panel A. Modified after Song et al [12].